“The investment in Cork is the biggest site investment in the history of our Life Science business”

24-May-2022

Merck is expanding its membrane and filtration manufacturing capabilities in Ireland. The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland. The ...

more

High margins in all three businesses despite challenging economic headwinds and increasing global uncertainty

12-May-2022

Merck achieved strong results in the first quarter of 2022. Net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter. All three business sectors contributed to this growth. The key drivers were the company’s Big3 businesses – the Process Solutions business of Life ...

more

Partnership with Administrative Management Committee of Wuxi National High-Tech Industrial Development Zone to jointly cultivate and enhance the life science ecosystem in Wuxi

02-May-2022

Merck signed an agreement with the Administrative Management Committee of Wuxi National High-Tech Industrial Development Zone to significantly expand Merck’s first Asia-Pacific Mobius® Single-Use manufacturing center in China. “For more than two decades, Merck’s Life Science business sector, ...

more

The groundbreaking aspect of her work centers on making circular dichroism ion spectroscopy feasible for large biomolecule ions

21-Apr-2022

Merck, a leading science and technology company, today presented Dr. Valérie Gabelica (44), Inserm, and Director of IECB, Pessac, France, with the 2022 Heinrich Emanuel Merck Award for Analytical Science. The award ceremony took place during the analytical conference EuroFAST2022, Nijmegen, the ...

more

Acquisition of MAST® Platform from Lonza, a Automated Bioreactor Sampling System

07-Apr-2022

Merck will advance its bioprocessing portfolio with the acquisition of the MAST® (Modular Automated Sampling Technology) platform from Lonza. The MAST® platform is an automated, aseptic bioreactor sampling system developed in Bend, Oregon, USA. The financial details of the deal were not ...

more

Greater investments in high-growth businesses

03-Mar-2022

Merck delivered record growth in fiscal 2021. In the course of the year, the company had already raised its business forecast three times. Group net sales increased by 12.3% to €19.7 billion compared with the previous year. All three business sectors, first and foremost Life Science, contributed ...

more

Company now offers comprehensive end-to-end services across mRNA value chain

24-Feb-2022

Merck announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD780million in cash. The business combination is expected to enable Merck’s Life Science business sector to provide ...

more

08-Feb-2022

Merck announced several organizational changes and a new operating model to support the long-term growth strategy of the Life Science business sector and to better serve the evolving needs of its global customers. “Science and technology are advancing at an unprecedented speed, and with that are ...

more

Recombinant protein has the potential to accelerate ischemic and hemorrhagic stroke recovery

24-Jan-2022

Merck announced that Elevian has been selected as the North American winner of its 2021 Advance Biotech Grant Program. The early-stage biotechnology company, which is based in Allston, Massachusetts, USA, was selected for its innovative recombinant protein, which has the potential to accelerate ...

more

Targeted acquisition to accelerate novel modalities service offering

07-Jan-2022

Merck has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD780million in cash. Exelead specializes in complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery ...

more